Despite the globally immunosuppressive BM microenvironment, the spontaneous development of endogenous specific anti-leukemic T-cell immunity directed against highly immunogenic NPM1-mutated-derived peptides has been observed in several patients with NPM1-mutated AML and may contribute to the maintenance of long-lasting CR and prolonged survival [16,19,27]. The gene discussed is NPM1; the disease is acute myeloid leukemia.